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Fibroblasts have been implicated in psoriatic inﬂammatory processes. The aim of the study was to evaluate soluble interleukin
2 receptor (sIL-2R), interleukin 6 (IL-6), and interleukin 8 (IL-8) plasma levels in psoriatic patients and IL-6 and IL-8 levels in
ﬁbroblastculturesupernatants.CytokineslevelsinplasmaandsupernatantsweremeasuredbyELISA.PlasmasIL-2R,IL-6,andIL-
8 levels were higher before the treatment in comparison to healthy controls (P<0.001) and decreased after treatment. Fibroblasts
from healthy controls, psoriatic lesional skin, and noninvolved psoriatic skin, when stimulated with tumor necrosis factor alpha,
released considerable amounts of IL-6 and IL-8. No signiﬁcant diﬀerence between healthy controls and psoriatic ﬁbroblasts was
observed. MonitoringplasmasIL-2Rlevels couldbe employed as areliable methodofpsoriasis activity. IL-8and IL-6plasma levels
seem to reﬂect psoriasis activity, and treatment response, respectively. Fibroblasts are not a major source of increased IL-6 and IL-8
production in psoriasis.
Copyright © 2006 Anna Zalewska et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Psoriasis is a chronic recurrent skin disease involving 1% to
2%ofhumanpopulationworldwide.Onhistology,itischar-
acterized by hyperproliferation of keratinocytes, vascular ex-
pansion, together with leukocyte inﬁltration. It is widely ac-
cepted that genetic predisposition and environmental factors
haveaprofoundeﬀectontheimmunesystemandplayacru-
cial role in triggering psoriatic lesion development. Psoriasis
isregardedasaTH1 disorderofautoimmunebackgroundand
it is postulated that changes in cytokine production both lo-
cally and systemically could be useful in monitoring activity
of the disease [1–4].
Fibroblasts are the most abundant cells in the connec-
tive tissue. From the historical point of view, these cells
were regarded as only quiescent elements forming stromal
framework for other cells in the connective tissue [5]. Not
long ago, ﬁbroblasts were discovered to initiate the earliest
molecular events, thus leading to inﬂammatory responses
[6]. So, in view of current ﬁndings, ﬁbroblasts should be re-
garded as active participants of tissue reactivity taking part
in inﬂammatory and remodelling processes. Literature data
point out ﬁbroblast involvement in psoriatic inﬂammation
[7, 8].
Interleukin 6 (IL-6) is a pleiotropic cytokine. Among its
characteristic actions are regulation of expression of other
cytokines, induction of diﬀerentiation and proliferation of
normal and malignant cells, inhibition of tumor growth. IL-
6 is also regarded as a major inducer of the acute-phase re-
sponse [9]. IL-6 is a component of normal human skin and
it was immunologically detected in basal keratinocytes, en-
dothelial cells, many mononuclear cells, ﬁbroblasts, and su-
doriparous ducts[10].IL-6hasbeensuggestedtofunctionas
an autocrine mitogen in psoriatic epidermis [11]. In psoria-
sis, intense labelling of the cytoplasm in the vicinity of ker-
atinocytes membranes was detected in the epidermal layers
and other skin appendages. Bearing in mind that this inter-
leukin acts synergistically with IL-1 and tumor necrosis fac-
tor alpha (TNF-α) further supports the hypothesis that IL-6
may contribute via its receptor action to epidermal growth
factor (EGF) function in modulating cell hyperproliferation
in psoriasis [10].
Interleukin 8 (IL-8) is the best-known chemokine. Its ac-
tion is greatly enhanced by IL-1 and TNF-α.I L - 8e x e r t sa
very strong chemotactic activity towards neutrophils [12].
Gearing et al studying diﬀerent cytokine levels, that is, IL-2,
IL-4, IL-6, IL-8, GM-CSF (granulocyte/macrophage colony-
stimulating factor) in aqueous extracts of stratum corneum2 Mediators of Inﬂammation
from psoriatic lesions and normal heel, found out that IL-
8 was the only biologically active cytokine to be elevated in
psoriatic lesional extracts [13].
TheaimofthestudywastoevaluatesIL-2R,IL-6,andIL-
8 plasma levels in psoriatic patients and Il-6 and IL-8 levels
in ﬁbroblast cultures.
MATERIALS AND METHODS
The study comprised 106 patients (30 females, 76 males),
aged 19–79 years (mean 44.9±13.6 years) hospitalized at the
Department of Dermatology and Venereology, Medical Uni-
versity of Ł´ od´ z, because of psoriasis vulgaris of moderate-
to-severe course. The control group comprised 40 healthy
volunteers (17 females, 23 males), aged 22–69 years (mean
46 ± 13.5 years). Psoriatic patients presented an active dis-
ease and the last exacerbation lasted from 2 to 8 weeks (mean
4 ± 1.6 weeks). The patients took only emollients and kera-
tolytic drugsbeforeadmittance to hospital. Asforcomorbid-
ity, hypertension was the most often discovered in psoriasis
patients (52 out of 106), then diabetes type II (7 out of 106),
and peptic ulcer (4 out of 106).
Blood was collected into pyrogen-free EDTA tubes in the
morning of the second day after admittance to hospital and 3
weeks after inpatient treatment, centrifuged within 30 min-
utes of collection (at 1000xg), and plasma was frozen in
−70◦C until further evaluated.
On the days of blood collection, clinical severity of the
disease was evaluated by PASI score (range 1–72 points) [14,
15].Beforeinpatienttreatment,PASIrangedfrom7.2to29.8
(mean 16.7±5.7), and 3 weeks thereafter ranged from 2.8 to
19.5 (mean 9.3 ± 4.1).
In hospital, the following treatment methods were em-
ployed: Ingram method (ie, anthralin plus UVB-NB irradi-
ation: 311nm, total cumulative dose mean 17.3J/cm2)r e -
ceived by 58 patients, anthralin alone received by 10 pa-
tients, Goeckerman method (ie, tar plus UVB-NB irradi-
ation: 311nm, total cumulative dose mean 18.5J/cm2)r e -
ceived by 10 patients, methotrexate (total dose mean 27.5mg
administered orally) received by 28 patients.
In psoriasis vulgaris patients, a 3mm punch biopsy was
taken from a representative psoriatic lesion located on the
external surface of the forearm from the plaque centre and
from perilesional noninvolved skin situated about 4–5mm
visible by the naked eye psoriatic plaque edge. In the con-
trol group, biopsies were taken once from the normal skin of
the forearm. The tissue was digested with 0.25% collagenase
and0.05%deoxyribonucleaseI(SigmaBioSciences,StLouis,
Mo, USA) in 1mL MEM (Biomed, Lublin, Poland) supple-
mented by 20% foetal calf serum (FCS; Hungarpol, Warsaw,
Poland),25mMHEPES,2mML-glutamine,100units/mLof
penicillin, and 100μg/mL of streptomycin (complete MEM,
all from Sigma BioSciences, St Louis, Mo, USA), at 37◦Cf o r
24 hours. Cells released during tissue digestion were trans-
ferred to tissue culture ﬂasks supplemented with 5mL of
completeMEMandculturedinCO2 incubator.Themedium
was changed twice a week until conﬂuent ﬁbroblast cultures
were obtained. Cells of passages 3 to 4 were used for the
current study. Three diﬀerent populations of ﬁbroblasts were
used: from normal skin of the healthy controls, from lesional
skin of psoriatic patients (psoriatic skin), and from perile-
sional skin of psoriatic plaques (noninvolved psoriatic skin).
Fibroblasts (105 cells/mL) were incubated with either TNF-α
(10ng/mL) or IL-8 (0.1μg/mL) for 6 hours, washed in cul-
ture medium and subsequently suspended in it, and further
incubated in pure culture medium for 21 hours when su-
pernatants were collected and frozen in −70◦C until further
evaluated.
In plasma sIL-2R, IL-6, and IL-8 and in supernatants, IL-
6 and IL-8 were assessed by ELISA method (sIL-2R by En-




All the patients and individuals participating in the study
gave their informed consent according to the Medical Uni-
versity of Ł´ od´ z Bioethic Committee requirements.
STATISTICAL ANALYSIS
Theobtainedresultswereexpressedasminimalandmaximal
values (range) and median value (Me). Numerical variables
distribution was assessed by λ-Kolmogorow test. Compar-
isons between groups were performed using Mann-Whitney
and Pearson correlation coeﬃcient (r). A P value less than
0.05 was considered to be statistically signiﬁcant.
RESULTS
Plasmameasurements
We observed signiﬁcantly increased plasma sIL-2R and IL-
6 levels before treatment than 3 weeks after inpatient treat-
ment and also when comparing with the healthy controls
(both P<0.001). No signiﬁcant diﬀerences in the above cy-
tokine plasma levels were found between psoriatic patients
after treatment and healthy controls (P>0.05). IL-8 plasma
levels before treatment were also signiﬁcantly higher than af-
ter treatment (P<0.01) and in comparison to healthy con-
trols (P<0.001). Still after 3 weeks of treatment in psoriatic
patients, IL-8 plasma levels were signiﬁcantly higher than in
the healthy controls (P<0.01) (Table 1).
Analysis of correlations between clinical parameters such
as sex, age of the patients, and their disease development,
time of the last exacerbation, PASI score, and sIL-2R, IL-6,
and IL-8 was performed. Both before and after treatment,
there was a positive correlation between sIL-2R and PASI
score (r = 0.69, P<0.001, and r = 0.75, P<0.001, resp)
(Figure 1). Also a positive correlation was observed between
age of the patients and sIL-2R plasma levels after the treat-
ment (r = 0.22, P<0.01).
Next, before treatment, a positive correlation between
plasma IL-8 levels and PASI score was observed (r = 0.25,
P<0.01). Additionally, also a positive correlation, how-
ever,aftertreatmentbetweenplasmaIL-6andPASIscorewas
found (r = 0.19, P<0.05). What is more, before treatment,Anna Zalewska et al 3
Table 1: Comparison of sIL-2R, IL-6, and IL-8 levels in plasma of psoriasis vulgaris patients before treatment and three weeks thereafter









range 203–8103 104–7851 437–2101 (a)-(b) P<0.001
(a)–(c) P<0.001
(b)-(c) P>0.05
Me 2166 1103 897
IL-6
(pg/mL)































































Figure 1: Correlation between sIL-2R plasma levels and PASI score before (PASI A) and after (PASI B) the treatment (y represents linear
regression equation; R2 represents determination coeﬃcient): (a) PASI A, y = 187.77x − 708.51, R2 = 0.4725; (b) PASI B, y = 234.67x −
814.12, R2 = 0.5604.
also a positive correlation between sIL-2R and IL-8 plasma
levels was discovered (r = 0.23, P<0.05).
Fibroblastcultures
Stimulation by either IL-8 or TNF-α caused huge production
of IL-8 by all types of ﬁbroblasts in comparison to baseline
conditions (70–100 times greater) (P<0.001). Also stimula-
tion with TNF-α led to considerable increase (10–20 times)
in IL-6 release by all ﬁbroblast populations in comparison to
baseline and IL-8 stimulation (P<0.001) (Table 2).
At baseline, healthy controls ﬁbroblasts released signif-
icantly higher amounts of IL-6 than noninvolved psoriatic
skin ﬁbroblasts (P<0.05). When stimulated with IL-8, no
statisticallysigniﬁcantdiﬀerenceinIL-6releasewasobserved
between all the studied ﬁbroblast cultures. However, when
stimulated with TNF-α, healthy controls ﬁbroblasts released
increased amounts of IL-6 in comparison to noninvolved
psoriatic skin ﬁbroblasts (P<0.05).
At baseline, no statistically signiﬁcant diﬀerences in IL-
8 release were observed between all types of ﬁbroblasts.
However, when stimulated with IL-8 or TNF-α, nonin-
volved psoriatic skin ﬁbroblasts released signiﬁcantly lower
amounts of IL-8 than both psoriatic skin ﬁbroblasts and
healthy controls ﬁbroblasts (P<0.05) (Table 2).
DISCUSSION
Interaction between T cells and keratinocytes is important
in pathogenesis of psoriasis by secretion of proinﬂammatory
cytokines and growth factors in psoriatic skin. Cellular re-
c e p t o rf o rI L - 2i se x p r e s s e do na c t i v a t e dTc e l l sa n dc a nb e
shed from the cells and measured as a soluble protein (sIL-
2R) [16]. Several cytokines have been increased in psoriasis,
either at local or systemic level or both including TNF-α,I L -
2, IL-6, IL-8, interferon gamma (IFN-γ), and transforming
growth factor alpha (TGF-α) which are regarded as hallmark
cytokines in psoriatic cytokine network [4, 7, 17–19]. For
decades, ﬁbroblasts seemed to be only “reserved” to active
participation in ﬁbrotic processes. Nowadays however, it is
postulated that these cells could actively participate in many
immunological processes including inﬂammation. However,4 Mediators of Inﬂammation
Table 2: Comparison of IL-6 and IL-8 levels in supernatants obtained from cultures of diﬀerent types of ﬁbroblasts. (a) Healthy controls:
ﬁbroblasts from normal skin of healthy volunteers; (b) psoriatic skin: ﬁbroblasts from lesional skin of psoriatic patients; (c) noninvolved





Type of ﬁbroblast culture
Stimulus Healthy controls Psoriatic skin Noninvolved P level
(a) (b) psoriatic skin (c)
Control
range 560–2265 300–3350 215–1550 (a)-(b) P>0.05
(a)–(c) P<0.05
(b)-(c) P>0.05 Me 1444 975 462
IL-6 IL-8 range 640–3390 465–3225 270–5465 (a)-(b)-(c) P>0.05
(pg/mL) (0.1μg/mL) Me 1225 967 795
TNF-α
(10ng/mL)
range 3570–94000 2890–32450 850–31880 (a)-(b) P>0.05
(a)–(c) P<0.05
(b)-(c) P>0.05 Me 25890 7738 4105
Control range 1540–8690 435–6080 435–6624 (a)-(b)-(c) - P>0.05
Me 2924 2803 1238
IL-8 IL-8 range 121780–405000 222684–416704 22412–2879913 (a)-(b) P>0.05
(a)–(c) P<0.05
(b)-(c) P<0.05 (pg/mL) (0.1 μg/mL) Me 312550 344399 199391
TNF-α
(10ng/mL)
range 126900–540872 69866–412728 25886–290981 (a)-(b) P>0.05
(a)–(c) P<0.05
(b)-(c) P<0.05 Me 319359 301979 123167
some reports deal with a possible involvement of ﬁbroblasts
in the development of this disease [7, 8, 20–22].
In our group of patients, plasma sIL-2R, IL-6, and IL-
8 levels were signiﬁcantly increased when comparing with
healthy controls, and subsequently they fell down parallel
with successful treatment in all the treatment groups. Our
results are in line with previous reports [23–33], but some
authors argue that isolated topical antipsoriatic treatment is
unable to lead to systemic changes [16]. However, Naldi re-
ported that conventional therapies despite being widely used
for decades, have not been thoroughly studied [34].
So, it seemed quite reasonable to examine plasma sIL-2R,
IL-6, and IL-8 levels and their correlation with diﬀerent clin-
ical parameters on quite numerous group of psoriasis vul-
garis patients. In our study, plasma sIL-2R levels, both be-
fore and after inpatient treatment, correlated in a positive
way with PASI. Also we demonstrated a positive correlation
between age of the patients and plasma sIL-2R levels after
treatment. This could result to some extent from the obser-
vation that the older the age of the patients, the longer du-
ration of the disease and maybe similar pattern of response
as regards disease activity evaluation. Thus, the older the pa-
tients, the higher plasma sIL-2R levels after successful antip-
soriatic treatment. Plasma sIL-2R levels could be regarded as
a marker of treatment response in psoriatic patients and em-
ployed in clinical practice.
Literature data point out increased serum IL-6 and IL-
8 levels in psoriasis [11, 35–38]. Some of the reports also
demonstrate that either lesional or serum levels of these cy-
tokines reﬂect to some extent disease activity and treatment
response [12, 39, 40]. In our group, a positive correlation
between plasma sIL-2R and IL-8 levels before treatment was
demonstrated suggesting that IL-8 could be regarded as an
additional, apart from sIL-2R, indicator of psoriasis activity.
We also observed a positive correlation between plasma IL-6
and sIL-2R levels after treatment. These results seem to point
out IL-6 as an indicator of treatment response.
Debets et al, studying normal and psoriatic ﬁbroblasts
and their secretion of IL-1, IL-6, IL-8, and TNF-α,c o n c e n -
trated on culture conditions, and discovered that FCS, in-
activated FCS, and human serum completely inhibited the
expression of IL-6 mRNA in all lesional psoriatic ﬁbroblasts
[8].Theauthorsdiscoveredthatpsoriaticandnormalﬁbrob-
lasts produced negligible amounts of IL-1 and TNF-α. Pso-
riatic ﬁbroblasts secrete low but increased amounts of IL-6
comparedtonormalﬁbroblastsunderserum-freeconditions
and production of IL-8 was comparable to that of IL-6. The
authors discovered that TNF-α stimulation leads to consid-
erable IL-6 release by normal ﬁbroblasts and much less pro-
nounced release of IL-8. Our experiments, however, show
that stimulation of IL-8, which is abundantly expressed in
psoriatic lesions and acts as a very strong chemoattractant
towards neutrophils gathered in psoriatic lesions, caused a
huge release of IL-8 by all types of ﬁbroblast. This could sug-
gest that ﬁbroblasts per se are very sensitive to this cytokine
and are able to further release IL-8 in an autocrine manner.
Also stimulation with TNF-α led to huge response in IL-8
release by all the studied ﬁbroblast populations.
The obtained results demonstrated that stimulation of ﬁ-
broblasts with either IL-8 or TNF-α could lead to potentia-
tion of inﬂammatory response. If we take a try to extrapolate
the obtained results to in vivo conditions, one could assumeAnna Zalewska et al 5
that ﬁbroblasts are involved in inﬂammatory response in the
development of psoriatic plaques, however not as most pow-
erful participants, which seems to be in agreement with the
literature data [22, 41, 42].
We did not observe signiﬁcant diﬀerences in cytokine re-
lease between ﬁbroblasts obtained from healthy controls skin
and ﬁbroblasts from lesional psoriatic skin. Other authors
also did not ﬁnd diﬀerence in many aspects of normal and
psoriatic ﬁbroblasts [8]. But is it worth pointing out that ﬁ-
broblasts from perilesional skin of psoriatic plaques demon-
strated signiﬁcant diﬀerences in cytokine release compared
to normal ﬁbroblasts from healthy controls, which could
suggest that direct surroundings of well-developed psoriatic
plaques are already aﬀected by pathological processes.
Among shortcoming of the present study one has to ad-
mit that unfortunately due to ethical reasons, measurements
of interleukin levels in cell supernatants were performed
only before the treatment. As for plasma level evaluation,
two measurements were performed in a 3-week interval. We
could have expanded the time interval, however inpatient
treatment usually does not last longer and we wanted the
patients to adhere to the employed treatment as strictly as
possible. Bearing in mind that about 30% to 40% of patients
demonstrate nonadherence, evaluation of inpatients when
they are separated from everyday worries and concentrated
almost only on treatment issues is most desired and reliable
[43, 44].
Worth mentioning is also one thing, that is, that extrapo-
lation of the obtained results in vitro into in vivo conditions
should be extremely cautiously performed. Direct and too
brave conclusions could be diﬃcult to draw and most con-
fusing to compare with data obtained in diﬀerent laboratory
conditions. It could be argued that plasma levels of exam-
ined cytokines were already performed and published a few
times but one has to bear in mind also the fact that cytokine
evaluation results may vary due to diﬀerent assays, individ-
ualvariationinstageofthedisease,demographicdiﬀerences,
and coexisting pathologies [29]. It should also be stressed
that in context of ﬁbroblasts, regarded as active participants
of inﬂammatory response, the obtained results seem to be of
value.
In conclusion, the obtained results conﬁrm usefulness of
plasma sIL-2R levels evaluation in monitoring psoriasis vul-
garis activity during treatment. Additionally, they also sup-
port the notion that ﬁbroblasts per se could be regarded
as important elements of inﬂammatory reactions in human
skin, however, they should rather not be treated as a major
source of increased production of IL-6 and IL-8 in psoriatic
skin.
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